Partner David Rosen was quoted in an article in Regulatory Focus, “FDA Plans Hearing on Biosimilar Competition, Development,” about the U.S. Food and Drug Administration’s plan to hold a public hearing to gather input on how it can facilitate the development of biosimilars and help bring them to market in a timely fashion.
Rosen said the legal issues delaying the launch of biosimilars are outside the FDA’s purview. “That’s in the hands of the courts and the companies that are involved,” he said.
He also said that the FDA could have a greater impact on competition by facilitating the development of more biosimilars, which in turn could lead to lower prices for products with multiple biosimilar competitors.
Rosen said the legal issues delaying the launch of biosimilars are outside the FDA’s purview. “That’s in the hands of the courts and the companies that are involved,” he said.
He also said that the FDA could have a greater impact on competition by facilitating the development of more biosimilars, which in turn could lead to lower prices for products with multiple biosimilar competitors.
People
Related News
May 28, 2025
In the News
Cliff Risman Featured on Hospitality Trends – Transactions at 'almost historic levels'
Foley & Lardner LLP partner Cliff Risman is featured in the Law360 Q&A, "Foley Hospitality Leader Talks Deals In Economic Uncertainty."
May 27, 2025
In the News
Kyle Faget Profiled on Health Care Evolution – 'Only just beginning to see what's possible'
Foley & Lardner LLP partner Kyle Faget is profiled by The Inspirational Leaders for her achievements and vision in health care law.
May 27, 2025
In the News
Foley's Silicon Valley Corporate Additions Featured in Legal Press
Foley & Lardner LLP partners Gurpreet Bal and Shaalu Mehra are highlighted in legal press for their recent arrival to the firm.